Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

DRUG:

D3L-001

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Company:

D3 Bio

Drug class:

HER2 inhibitor, CD47 inhibitor

Related drugs:

‹

anti-CD47 monoclonal antibody (0)

PF-07901800 (0)

trastuzumab (407)

lapatinib (107)

neratinib (102)

trastuzumab-pkrb (24)

margetuximab-cmkb (18)

poziotinib (17)

zenocutuzumab-zbco (16)

mobocertinib (12)

trastuzumab-dttb (11)

zanidatamab-hrii (10)

trastuzumab-strf (9)

trastuzumab-anns (9)

trastuzumab-dkst (9)

trastuzumab-qyyp (9)

Undisclosed allogeneic Vγ9Vδ2 HER2-TAC T (4)

pertuzumab/trastuzumab/hyaluronidase-zzxf (3)

trastuzumab-IFN-β mutein (3)

trastuzumab/hyaluronidase-oysk (2)

JBJ-08–178–01 (2)

Hercease (trastuzumab biosimilar) (1)

BAY 2927088 (1)

HERtiCAD (trastuzumab biosimilar) (1)

Hervelous (trastuzumab biosimilar) (1)

EG12014 (trastuzumab biosimilar) (1)

TX05 (trastuzumab biosimilar) (1)

ALT02 (trastuzumab biosimilar) (0)

trastuzumab biosimilar (AP062) (0)

DA 3111 (trastuzumab biosimilar) (0)

HER-2/neu peptide vaccine (0)

HER2 t-haNK (0)

HLX11 (pertuzumab biosimilar) (0)

Hervycta (trastuzumab biosimilar) (0)

JNJ-26483327 (0)

MVA-BN-HER2 (0)

NeuCeptin (trastuzumab biosimilar) (0)

nelipepimut-S (0)

lapuleucel-T (0)

ertumaxomab (0)

trastuzumab biosimilar (SIBP-01) (0)

TAC100-HER2 (0)

glycooptimized trastuzumab-GEX (0)

TrastuRel (trastuzumab biosimilar) (0)

Undisclosed HER2Bi-armed ATC (0)

trastuzumab biosimilar (0)

trastuzumab biosimilar (0)

ABBV-IMAB-TJC4 (2)

PF-07257876 (0)

anti-CD47 monoclonal antibody (0)

PF-07901800 (0)

›

HER-2 positive	Gastric Cancer	HER-2 positive	Gastric Cancer	D3L-001 Sensitive: C2 – Inclusion Criteria D3L-001 Sensitive : C2	D3L-001 Sensitive: C2 – Inclusion Criteria D3L-001 Sensitive : C2
HER-2 positive	HER2 Positive Breast Cancer	HER-2 positive	HER2 Positive Breast Cancer	D3L-001 Sensitive: D – Preclinical D3L-001 Sensitive : D	D3L-001 Sensitive: D – Preclinical D3L-001 Sensitive : D
HER-2 positive	Gastric Cancer	HER-2 positive	Gastric Cancer	pertuzumab + D3L-001 Sensitive: D – Preclinical pertuzumab + D3L-001 Sensitive : D	pertuzumab + D3L-001 Sensitive: D – Preclinical pertuzumab + D3L-001 Sensitive : D
HER-2 positive	HER2 Positive Breast Cancer	HER-2 positive	HER2 Positive Breast Cancer	pertuzumab + D3L-001 Sensitive: D – Preclinical pertuzumab + D3L-001 Sensitive : D	pertuzumab + D3L-001 Sensitive: D – Preclinical pertuzumab + D3L-001 Sensitive : D
CD47 positive + HER-2 positive	Solid Tumor	CD47 positive + HER-2 positive	Solid Tumor	D3L-001 Sensitive: D – Preclinical D3L-001 Sensitive : D	D3L-001 Sensitive: D – Preclinical D3L-001 Sensitive : D
CD47 positive + HER-2 positive	Gastric Cancer	CD47 positive + HER-2 positive	Gastric Cancer	D3L-001 Sensitive: D – Preclinical D3L-001 Sensitive : D	D3L-001 Sensitive: D – Preclinical D3L-001 Sensitive : D
CD47 positive	HER2 Positive Breast Cancer	CD47 positive	HER2 Positive Breast Cancer	D3L-001 Sensitive: D – Preclinical D3L-001 Sensitive : D	D3L-001 Sensitive: D – Preclinical D3L-001 Sensitive : D